New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls.
Read the Q3 2026 report
CASI Pharmaceuticals Inc. (CASIF) vs Neuphoria Therapeutics Inc. (NEUP)
- CASI Pharmaceuticals Inc. CASIF 0.11 +10.00%
- Neuphoria Therapeutics Inc. NEUP 2.35 +1.29%
CASI Pharmaceuticals Inc. and Neuphoria Therapeutics Inc. are both Biotechnology companies. CASI Pharmaceuticals Inc. and Neuphoria Therapeutics Inc. are of similar size ($12.6M and $12.4M). Across the 11 metrics below, CASI Pharmaceuticals Inc. leads on 6 and Neuphoria Therapeutics Inc. on 5.
Valuation
Profitability
| Metric | CASIF | NEUP | Biotechnology median |
|---|---|---|---|
| Gross margin | 48.65% | — | 70.18% |
| Operating margin | (206.87%) | — | 0.00% |
| Net margin | (232.03%) | — | 0.00% |
| Free cash flow margin | — | — | 0.00% |
| Return on equity | 271.28% | (27.63%) | (51.58%) |
| Return on assets | (121.17%) | (18.26%) | (45.91%) |
| Return on invested capital | 0.00% | (186.04%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack